Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mind Medicine (MindMed) Inc. - Common Shares (NQ:MNMD)

7.600 +0.590 (+8.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2
...
21 22 23 24 25 26 27 28 Next >
MNMD Stock Pops Higher After MindMed Unveils ‘Psychedelic’ Data
MNMD stock is up today after MindMed reported positive findings on the interactions between psilocybin and an antidepressant. 
Via InvestorPlace
Antidepressants Can Be Used During Psilocybin Treatment, A New MindMed & Liechti Lab Study Finds
Psychedelics-focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced the publication of its first data on the interaction of a selective... 
Via Benzinga
Psychedelic Drug Stocks Continued To Decline Last Week
The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November. 
Via Talk Markets
3 Psychedelic Stocks for Potential Out-of-This-World Gains
Psychedelic drugs could be a major game-changer when it comes to treating mental illness. All as psilocybin, LSD, and MDMA show progress. 
Via InvestorPlace
MindMed Q3 Earnings: Big Improvement, Kicks Off Sleep & Cognitive Study With Dose Low-Dose LSD
MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a biotech company developing psychedelic-inspired therapies, announced its financial results late Monday for the third quarter... 
Via Benzinga
Cannabis Movers & Shakers: Mind Medicine, Avant Brands, Delic, Agrify, Ascend Wellness, Pure Beauty
Mind Medicine Appoints Maria A. Oquendo To Scientific Advisory Board Psychedelic-focused biotech company Mind Medicine Inc. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others
Compass Pathways reported 
Via Talk Markets
Behind the Wall: Psychedelics Have “Absolutely Transformational” Potential
Is now the time to invest in psychedelic stocks? Dustin Robinson, founder of venture capital firm Iter Investments, says yes and explains why. 
Via InvestorPlace
Compass Pathways Goes On Bad Trip, Despite 'Positive' Results From Psilocybin Trial
Shares plunged, despite a psilocybin-based drug reducing depression in a trial. 
Via Investor's Business Daily
Compass Pathways 2.0: A New Rally In Psychedelic Stocks?
Compass Pathways' IPO sparked a sector-wide rally in 2020. Now CMPS is on the move again. Is history about to repeat? 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
How This Company Is Using Psychedelic Medicines and Therapies to Treat Addiction and Mental Illness
Courtesy of: MindMed The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored c... 
Via Benzinga
Magic Mushrooms and Ecstasy: New Treatment For Autism Spectrum Disorders?
Much like cannabis, psychedelics are catch... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Psyched: MindMed's MDMA Program For Autism, Small Pharma's New Patent, NovaMentis' Orphan Drug Designation
The Week In Psychedelics: 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Biotech Companies Are Embracing the Growing Psychedelic Drug Market To Confront a Global Increase in Depression and Anxiety
Image by 3D Animation Production Company from Pixabay The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team... 
Via Benzinga
Phase 2 Trial On Ayahuasca's Active Ingredient Puts Small Pharma On Track To Winning The Psychedelics Race
Small Pharma Inc. (OTCQB:DMTTF) (TSXV: 
Via Benzinga
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
The Week In Psychedelics 
Via Benzinga
Forget The Hype: The Psychedelic Stocks Sector Went Down In The Third Quarter Of 2021
Despite the prevailing hype, the psychedelic sector went down considerably last quarter (July through September) and has gone down even further so far this month. 
Via Talk Markets
Psychedelic Stocks: Financial Strength, Growth Potential, Compelling Valuations
Blue-chip stocks: grossly inflated valuations and loaded with debt. Psychedelic stocks: lean valuations and loaded with cash. A very attractive option in uncertain markets. 
Via Talk Markets
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S... 
Via Benzinga
Psyched: Seattle Decriminalizes Psychedelics, Psilocybin Increases Emotions From Music, Novamind's Palliative Care Program
The Week In Psychedelics 
Via Benzinga
Former Tilray CEO Joins Psychedelics Company
More big names in cannabis are switching to psychedelics. Greg Engel, former CEO of Tilray (NASDAQ: 
Via Benzinga
Topics Cannabis
Exposures Cannabis
MindMed Teams Up With Sphere Health To Identify Biomarkers Associated With Anxiety & Depression
Psychedelic–focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) disclosed on Tuesday that it has agreed to partner with Sphere Health to... 
Via Benzinga
Cannabis Movers & Shakers: Leafly Holdings, Linneo Health, Flowhub, MindMed
Leafly Holdings Taps Suresh Krishnaswamy As New CFO The cannabis information platform Leafly Holdings, Inc. recently disclosed ... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Psychedelic Front Runners MindMed , BioXcel Patent System To Identify Agitation
This article by Gaurav Dubey was originally published on 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
COVID Tests, THC Patches, Psychedelics: Xphyto Therapeutics Does it All
Image by Shameer Pk from Pixabay From 25-minute COVID-19 lab tests to psychedelic medicine that is poised to address mental health conditions like PTSD, XPhyto Therapeutics (... 
Via Benzinga
Exposures COVID-19
6 Psychedelic Stocks With Buy Rating: Why Are They Good Investments?
This article by Jason Najum was originally published on 
Via Benzinga
Four Stocks Disrupting Mental Health To Keep An Eye On At Benzinga's Healthcare Conference
The healthcare sector is booming and startups are the driving force behind the innovations that will affect the future of life on earth. ... 
Via Benzinga
Digital Therapeutics And The Future Of Psychedelic Medicine
Digital health and therapeutics will play a crucial role in the future of medicine. Across medical and mental health industries, companies are real... 
Via Benzinga
Psyched: Delic Buys 10 Ketamine Clinics For $10M, Atai Launches Ibogaine Human Trials, Small Pharma Concludes Phase 1 DMT Study
The Week In Psychedelics: 
Via Benzinga
Which Psychedelic Stock ETF Is Right For You?
This week the AdvisorShares Psychedelics ETF began trading on the NYSE Arca. Here we compare the make-up of the now 3 psychedelic stock ETFs and two tracking indexes. 
Via Talk Markets
< Previous 1 2
...
21 22 23 24 25 26 27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.